To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC80100 | 5-Diazomethane quinoxaline Featured |
5-Diazomethane quinoxaline is a novel derivatization reagent. 5-Diazomethane quinoxaline is used for the detection of phosphorylated metabolites.
More description
|
|
| DC28558 | BCL6-IN-3 Featured |
BCL6-IN-3 (example 20a) is a B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity, extracted from patent WO2018215801A1. BCL6-IN-3 (example 20a) exhibits a GI50 of 70 nM in SU-DHL4 cells.
More description
|
|
| DCC1608 | Cx08005 Featured |
CX08005 is a competitive PTP1B inhibitor. CX08005 can directly enhance the action of insulin in vivo and in vitro and improve insulin resistance.
More description
|
|
| DC34504 | Amthamine Dihydrobromide Featured |
Amthamine is a histamine receptor (H1R-H4R) agonist. Amthamine can produce liver congestion and necrosis of liver cells. Amthamine can be used to study the induction effect of H1R-H4 agonist on hepatotoxicity.
More description
|
|
| DCC4830 | Sod1-derlin-1 Inhibitor 56-20 Featured |
SOD1-Derlin-1 inhibitor-1 (compound 56-20) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-1 inhibits SOD1G93A-Derlin-1 complex with an IC50 value of 7.11 μM.
More description
|
|
| DC43652 | Merck-22-6 Featured |
Merck-22-6(compound 7) is an allosteric dual Akt1 and Akt2 inhibitor (IC50=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells
More description
|
|
| DC79780 | (S)-SCH-23390 hydrochloride Featured |
(S)-SCH-23390 (hydrochloride) is the S-enantiomer of SCH-23390. SCH-23390 is a dopamine D1-like receptor antagonist (with Ki values of 0.2 nM and 0.3 nM for the D1 and D5 receptor subtypes, respectively).
More description
|
|
| DC76520 | SCH-23390 Featured |
SCH-23390 is a dopamine D1-like receptor antagonist (with Ki values of 0.2 nM and 0.3 nM for the D1 and D5 receptor subtypes, respectively). SCH-23390 can shorten the latency period for cocaine-induced lever pressing behavior in rats. SCH-23390 can also eliminate generalized seizures caused by chemical convulsants, such as arecoline and strychnine, and is used in research on neurological disorders related to the dopamine system.
More description
|
|
| DCC1702 | Dc-s239 Featured |
Novel, Potent and Selective Histone Methyltransferase SET7 Inhibitor
More description
|
|
| DC11745 | BMS-22 Featured |
A potent, selective, allosteric CCR2 antagonist with binding IC50 of 5.1 nM.
More description
|
|
| DC20983 | Linopirdine Featured |
Linopirdine (DuP 996) is an orally active, selective M-type K+ current (IM; Kv7; KCNQ Channels) inhibitor with an IC50 of 2.4 μM. Linopirdine is a TRPV1 agonist. Linopirdine, a putative cognition enhancing agent, increases acetylcholine release in rat brain tissue.
More description
|
|
| DC11020 | SOD1-Derlin-1 inhibitor 56-59 Featured |
SOD1-Derlin-1 inhibitor 56-59 is a cell-permeable, small molecule inhibitor of SOD1-Derlin-1 interaction, target SOD1 DBR and clearly attenuates the interactions of Derlin-1 with 122 types of SOD1mut in the cell-based co-immunoprecipitation assay.
More description
|
|
| DC45063 | GPR35 agonist 2 Featured |
GPR35 agonist 2 (compound 11) is a potent agonist of GPR35, with EC50s of 26 and 3.2 nM in the β-arrestin and Ca2+ release assay, respectively.
More description
|
|
| DCC3590 | Ncrw0005-f05 Featured |
NCRW0005-F05 is a small-molecule inhibitor reported to target the Wnt/β-catenin signaling pathway with activity in vitro. It suppresses β-catenin–dependent transcription in a concentration-dependent manner, with reported IC50 values in the low micromolar range (~1–10 µM) in reporter assays. NCRW0005-F05 reduces expression of Wnt target genes such as c-Myc and cyclin D1, leading to decreased proliferation in Wnt-driven cancer cell models.
More description
|
|
| DC70660 | NPD4928 Featured |
NPD4928 (NPD 4928) is a small molecule that enhances ferroptosis via inhibition of ferroptosis suppressor protein 1 (FSP1).NPD4928 enhanced the sensitivity of various cancer cells to GPX4 inhibitor RSL3.
More description
|
|
| DC31263 | ONT-093 Featured |
ONT-093, also known as OC-144-093, is an orally bioavailable P-glycoprotein pump inhibitor, for the potential reversal of multidrug resistance in patients undergoing cancer chemotherapy. ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. OC144-093 is the least non-specifically toxic Pgp inhibitor described to date, with an average cytostatic IC50 of >60 microM in 15 cell types. OC144-093 may represent an ideal candidate for use in enhancement of AED blood-brain barrier penetration.
More description
|
|
| DC80295 | Ponometrep(BBO-11818) Featured |
BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC50=28-120 nM). BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab, anti-PD-1 antibody or PI3Kα inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer.
More description
|
|
| DC74605 | EDI048 Featured |
EDI048 (compound 1.16) is an orally active Cryptosporidium PI4K inhibitor for the research of cryptosporidiosis.
More description
|
|
| DC48051 | ARN19702 Featured |
ARN19702 is a selective, orally active, reversible, and brain-penetrant N-acylethanolamine acid amidase (NAAA) inhibitor with an IC50 of 230 nM for human NAAA. ARN19702 has pain relief effects.
More description
|
|
| DC46491 | BAY-8400 Featured |
BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor with IC50 of 81 nM. BAY-8400 shows synergistic activity of DNA-PK inhibition when combined with DNA damage inducing cancer therapy, like targeted alpha radiation.
More description
|
|
| DC47413 | Eliapixant Featured |
Eliapixant (BAY1817080) is a highly potent and selective P2X3 receptor antagonist with a mean IC50 of 8 nM.
More description
|
|
| DC47967 | KCNQ2/3 activator-1 Featured |
KCNQ2/3 activator-1 is an activator of Kv7.2/Kv7.3 (KCNQ2/3) potassium channel. KCNQ2/3 activator-1 has the potential in relieving pain (the main problem from medical treatment) (extracted from patent WO2021113757A1, compound A).
More description
|
|
| DC46276 | BRD0639 Featured |
BRD0639 is a first-in-class inhibitor of the PRMT5-substrate adaptor interaction. BRD0639 is a PRMT5 binding motif (PBM)-competitive agent that can support studies of PBM dependent PRMT5 activities.
More description
|
|
| DCC5320 | UMB298 Featured |
UMB298 is a potent and selective CBP/P300 bromodomain inhibitor.
More description
|
|
| DCC4235 | Pqsr Antagonist M64 Featured |
Quorum sensing modulator as a PqsR antagonist
More description
|
|
| DC73565 | SZU-101 Featured |
SZU101 is a small molecule TLR7 agonist that directly activates, induces reporter activity (23-fold) in a TLR7-NF-kB reporter system expressed in HEK-293 cells TLR7 signalling.
More description
|
|
| DC73770 | TPN171 Featured |
TPN171 (TPN-171) is a highly potent, selective phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 0.62 nM, 32-fold selectivity over PDE6.
More description
|
|
| DC20019 | Flagelin 22(TFA) |
Flagelin 22 TFA, a fragment of bacterial flagellin, is an effective elicitor in both plants and algae.
More description
|
|
| DC45440 | 3'-Methoxyapiin |
3'-Methoxyapiin (Graveobioside B) is a flavone. 3'-Methoxyapiin can be found in Uraria crinite and celery.
More description
|
|
| DC9794 | SU-10994 |
SU-10994 is a novel VEGFR inhibitor.
More description
|
|